These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16622844)

  • 21. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients.
    Tanaka T; Selzner N; Therapondos G; Renner EL; Lilly LB
    Transpl Int; 2013 Jan; 26(1):42-9. PubMed ID: 23137287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy.
    Berenguer M; Aguilera V; Rubín A; Ortíz C; Jimenez M; Prieto M
    J Hepatol; 2012 Jun; 56(6):1310-6. PubMed ID: 22314429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Post-transplant hepatitis C. Immunosuppression and antiviral treatment].
    Olivera Martínez MA
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S67-70. PubMed ID: 12712858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hepatitis C after liver transplantation].
    Samuel D; Roche B; Feray C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B231-7. PubMed ID: 12180295
    [No Abstract]   [Full Text] [Related]  

  • 25. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.
    Dharancy S; Coilly A; Fougerou-Leurent C; Duvoux C; Kamar N; Leroy V; Tran A; Houssel-Debry P; Canva V; Moreno C; Conti F; Dumortier J; Di Martino V; Radenne S; De Ledinghen V; D'Alteroche L; Silvain C; Besch C; Perré P; Botta-Fridlund D; Francoz C; Habersetzer F; Montialoux H; Abergel A; Debette-Gratien M; Rohel A; Rossignol E; Samuel D; Duclos-Vallée JC; Pageaux GP;
    Am J Transplant; 2017 Nov; 17(11):2869-2878. PubMed ID: 28898563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C, interferon, and risk of rejection after liver transplantation.
    Samuel D
    Liver Transpl; 2004 Jul; 10(7):868-71. PubMed ID: 15237370
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of recurrent hepatitis C].
    Berenguer M
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():63-7. PubMed ID: 11968347
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of recurrent hepatitis C in liver transplant recipients.
    Biggins SW; Terrault NA
    Infect Dis Clin North Am; 2006 Mar; 20(1):155-74. PubMed ID: 16527654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation.
    Crespo G; Carrión JA; Coto-Llerena M; Mariño Z; Lens S; Pérez-Del-Pulgar S; García-Retortillo M; Miquel R; Bosch J; Navasa M; Forns X
    J Gastroenterol; 2013 Jun; 48(6):762-9. PubMed ID: 23011083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy.
    Werner CR; Egetemeyr DP; Nadalin S; Königsrainer A; Malek NP; Lauer UM; Berg CP
    Z Gastroenterol; 2014 Jan; 52(1):27-34. PubMed ID: 24420796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
    Nookala AU; Crismale J; Schiano T; Te H; Ahn J; Robertazzi S; Rodigas C; Satoskar R; Kc M; Hassan M; Smith C
    Clin Transplant; 2018 Mar; 32(3):e13198. PubMed ID: 29323755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors of sustained virological response for recurrent hepatitis C virus after liver transplantation: the hungarian experience.
    Nemes B; Gelley F; Zádori G; Kiss A; Nagy P; Gerlei Z; Lengyel G; Sárváry E
    Transplant Proc; 2012 Sep; 44(7):2162-3. PubMed ID: 22974942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of simultaneous splenectomy in liver transplant recipients with hepatitis C virus.
    Morimoto H; Ishiyama K; Ishifuro M; Ohira M; Ide K; Tanaka Y; Tahara H; Teraoka Y; Yamashita M; Abe T; Hashimoto S; Hirata F; Tanimine N; Saeki Y; Shimizu S; Sakai H; Yano T; Tashiro H; Ohdan H
    Transplant Proc; 2014 Apr; 46(3):770-3. PubMed ID: 24767345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C.
    Crespo G; Lens S; Gambato M; Carrión JA; Mariño Z; Londoño MC; Miquel R; Bosch J; Navasa M; Forns X
    Am J Transplant; 2014 Feb; 14(2):375-83. PubMed ID: 24410892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic model for early acute rejection after liver transplantation.
    Gómez-Manero N; Herrero JI; Quiroga J; Sangro B; Pardo F; Cienfuegos JA; Prieto J
    Liver Transpl; 2001 Mar; 7(3):246-54. PubMed ID: 11244167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination.
    Kasarala G; Choi S; Lopez K; Britt RB; Boatright C; Tillmann HL
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064152
    [No Abstract]   [Full Text] [Related]  

  • 37. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 38. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
    Shire N; Koziel MJ
    Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
    [No Abstract]   [Full Text] [Related]  

  • 39. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy.
    Chan C; Schiano T; Agudelo E; Paul Haydek J; Hoteit M; Laurito MP; Norvell JP; Terrault N; Verna EC; Yang A; Levitsky J
    Am J Transplant; 2018 Oct; 18(10):2506-2512. PubMed ID: 30075485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.